CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06157892
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:12.781651+00:00
Published At: 2026-03-17T00:00:00+00:00
Record Updated At: 2026-03-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Breast Neoplasms", "Gastroesophageal Junction Adenocarcinoma", "HER2 Low Breast Neoplasms", "HER2 Positive Breast Neoplasms", "Stomach Neoplasms", "Triple Negative Breast Neoplasms", "Metastatic Breast Cancer", "Metastatic Gastric Cancer", "Advanced Breast Cancer", "Advanced Gastric Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-17"
protocolSection.identificationModule.nctId: "NCT06157892"
protocolSection.identificationModule.officialTitle: "A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.